Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).
Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).
Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).
Maria E. Cabanillas, MD, an oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses how to deliver the optimal surgical approach to patients with medullary thyroid cancer.
Maria E. Cabanillas, MD, oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses current systemic treatments in medullary thyroid cancer, along with the potential for peptide receptor radionuclide therapy.
Investigators at the Perelman School of Medicine at the University of Pennsylvania have recently initiated a clinical trial evaluating a novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with advanced incurable medullary thyroid cancer.
